Your browser is no longer supported. Please, upgrade your browser.
Iovance Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-1.93 Insider Own0.77% Shs Outstand146.49M Perf Week1.07%
Market Cap7.26B Forward P/E- EPS next Y-2.04 Insider Trans0.00% Shs Float135.48M Perf Month6.78%
Income-254.80M PEG- EPS next Q-0.44 Inst Own99.30% Short Float12.12% Perf Quarter41.64%
Sales- P/S- EPS this Y-25.10% Inst Trans0.03% Short Ratio13.23 Perf Half Y66.81%
Book/sh4.86 P/B10.51 EPS next Y-10.30% ROA-45.60% Target Price49.73 Perf Year115.08%
Cash/sh5.02 P/C10.17 EPS next 5Y- ROE-50.60% 52W Range18.70 - 53.78 Perf YTD10.04%
Dividend- P/FCF- EPS past 5Y-27.00% ROI- 52W High-5.05% Beta0.81
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low173.05% ATR3.07
Employees148 Current Ratio11.20 Sales Q/Q- Oper. Margin- RSI (14)61.14 Volatility7.12% 6.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-0.20% Profit Margin- Rel Volume0.79 Prev Close52.03
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume1.24M Price51.06
Recom1.80 SMA205.45% SMA5016.39% SMA20045.57% Volume981,237 Change-1.86%
Dec-15-20Downgrade H.C. Wainwright Buy → Neutral
Oct-06-20Downgrade Wells Fargo Overweight → Equal Weight
Apr-22-20Initiated Mizuho Buy $61
Mar-04-20Initiated Barclays Overweight $45
Feb-26-20Reiterated Oppenheimer Outperform $32 → $35
Feb-26-20Reiterated H.C. Wainwright Buy $32 → $36
Dec-18-19Initiated JMP Securities Mkt Outperform $38
Oct-01-19Initiated Stifel Buy $27
Apr-29-19Initiated Piper Jaffray Overweight $20
Feb-28-19Reiterated Chardan Capital Markets Buy $30 → $20
Feb-07-19Initiated Robert W. Baird Outperform
Dec-31-18Resumed B. Riley FBR Buy $24
Jul-06-18Reiterated Chardan Capital Markets Buy
Apr-10-18Upgrade B. Riley FBR, Inc. Neutral → Buy $22
Mar-13-18Reiterated B. Riley FBR, Inc. Neutral $18.50 → $22
Feb-23-18Downgrade B. Riley FBR, Inc. Buy → Neutral $18 → $18.50
Jan-25-18Reiterated H.C. Wainwright Buy $16 → $22
Nov-01-17Reiterated B. Riley FBR, Inc. Buy $17.50 → $18
Dec-28-20 07:30AM  
Dec-15-20 02:24PM  
Dec-14-20 07:00AM  
Dec-05-20 11:32AM  
Nov-30-20 07:21AM  
Nov-09-20 08:58AM  
Nov-05-20 04:00PM  
Oct-30-20 07:00AM  
Oct-29-20 11:11AM  
Oct-28-20 07:45AM  
Oct-14-20 05:01PM  
Oct-09-20 10:12PM  
Oct-08-20 05:48PM  
Oct-07-20 10:49AM  
Oct-06-20 09:43AM  
Oct-05-20 04:01PM  
Sep-07-20 03:46PM  
Sep-05-20 11:32AM  
Aug-10-20 11:22AM  
Aug-07-20 07:30AM  
Aug-06-20 04:01PM  
Aug-04-20 05:33PM  
Jul-23-20 07:30AM  
Jul-15-20 01:15PM  
Jul-14-20 12:49PM  
Jul-01-20 07:11AM  
Jun-08-20 04:01PM  
Jun-04-20 11:31AM  
Jun-02-20 04:01PM  
Jun-01-20 09:20AM  
May-29-20 08:01AM  
May-28-20 09:30PM  
May-27-20 04:20PM  
May-13-20 05:01PM  
May-11-20 11:13PM  
May-08-20 11:46AM  
May-06-20 11:26AM  
May-05-20 04:01PM  
Apr-30-20 06:13PM  
Apr-29-20 12:01PM  
Apr-27-20 04:01PM  
Apr-17-20 08:43AM  
Apr-16-20 04:11PM  
Apr-13-20 05:14PM  
Mar-27-20 02:55PM  
Mar-11-20 09:18AM  
Mar-10-20 08:23AM  
Mar-02-20 04:01PM  
Feb-25-20 05:46PM  
Feb-19-20 07:00AM  
Feb-12-20 07:00AM  
Jan-15-20 08:00AM  
Jan-13-20 04:15PM  
Jan-12-20 04:30PM  
Dec-26-19 11:25AM  
Dec-23-19 05:40AM  
Dec-16-19 03:55PM  
Dec-04-19 08:03PM  
Dec-02-19 07:00AM  
Nov-21-19 07:00AM  
Nov-08-19 02:58PM  
Nov-07-19 04:32PM  
Nov-04-19 04:01PM  
Oct-31-19 04:43PM  
Oct-21-19 10:55AM  
Oct-02-19 07:00AM  
Oct-01-19 01:48PM  
Sep-27-19 04:30PM  
Sep-19-19 02:07PM  
Sep-16-19 12:00PM  
Aug-27-19 04:57PM  
Aug-26-19 04:30PM  
Aug-14-19 01:04PM  
Aug-02-19 10:24PM  
Aug-01-19 04:01PM  
Jul-29-19 03:00PM  
Jul-26-19 07:00AM  
Jul-18-19 08:00AM  
Jul-10-19 12:46PM  
Jul-08-19 06:22PM  
Jul-02-19 08:50AM  
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.